{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"LUOSICNS","nct_id":"NCT03769103","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=luosicns-nct03769103. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Stereotactic radiotherapy will be delivered in 1-5 fractions to each brain metastases according to the volume and location of the metastases and clinician discretion. Osimertinib will start 1-7 days post radiotherapy.","label":"SRS + Osimertinib","type":"ACTIVE_COMPARATOR"},{"description":"Osimertinib 80mg PO daily","label":"Osimertinib alone","type":"EXPERIMENTAL"}],"collaborators":["AstraZeneca","Princess Margaret Hospital, Canada","Sunnybrook Health Sciences Centre"],"completion_date":{"date":"2025-04","type":"ESTIMATED"},"conditions":["Lung Cancer Non-small Cell Stage IV","Brain Metastases"],"enrollment":{"count":40,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Osimertinib","otherNames":[],"type":"DRUG"},{"name":"Stereotactic radiotherapy","otherNames":[],"type":"RADIATION"}],"last_update":"2024-10-31","lead_sponsor":"British Columbia Cancer Agency","official_title":"Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Intracranial progression free survival","timeFrame":"1 year"}],"references":[{"citation":"Lee CK, Lefresne S, Soon YY, Robledo K, Nichol A, Sahgal A, Pinkham MB, Melosky B, Huang Y, McDermott R, Tham IWK, Parmar A, Tey JCS, Liu M, Solomon BJ, Sacher A, Leong CN, Laskin J, Koh WY, Menjak IB, Ang Y, Shultz DB, Low JL, Doherty M, Yong C, Lim MC, Tan AP, Soo RA, Hegi-Johnson F, Ho C. Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials. J Thorac Oncol. 2026 May;21(5):103549. doi: 10.1016/j.jtho.2026.01.001. Epub 2026 Jan 12.","pmid":"41534788","type":"DERIVED"}],"start_date":{"date":"2019-03-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC","url":"https://clinicaltrials.gov/study/NCT03769103"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/luosicns-nct03769103"}